Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable.

Trump has warned that a wave of executive orders would be signed upon him returning to the White House. He and top aide ...

Viking Therapeutics investors face challenges as stock plummets, cash runway helps but betting on early stage biopharma ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...

NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novo ...

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including ...

Generics businesses achieve pretty defendable margins, yet their valuations are at material discounts to most of the Big ...

Health care, ride sharing, and the emerging world of YouTube entertainers are among industries leading investors have picked ...

Medicare announced plans to negotiate lower prices for 15 costly drugs, including Ozempic, Wegovy, and Trelegy Ellipta, ...

Novo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release selecting the company’s popular ...

The medicines may not only suppress appetite but also help curb alcoholism and other addictions. Read more at straitstimes.com.